Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Giovanni Targher, Christopher Paul Day, Enzo Bonora · New England Journal of Medicine · 2010
Growing evidence suggests that nonalcoholic fatty liver disease is associated with an increased risk of cardiovascular disease beyond that conferred by established risk factors.
Cited by 1,910 works. doi:10.1056/nejmra0912063
Authors
References
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆
- Nonalcoholic Fatty Liver Disease
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
- Inflammation and insulin resistance
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
- Toll-like Receptor 4 Polymorphisms and Atherogenesis
- Obesity, Inflammation, and Insulin Resistance